VCYTNasdaqServices-Medical LaboratoriesFiscal year ends December 31
VERACYTE, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 31, 2026
$43.80+0.68 (+1.58%)
Close on Oct 19, 2026
- Market cap
- $3.59B
- P/E (TTM)
- 31.3
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2011 to 2025
Gross margin
70.1%
Operating margin
11.2%+41.3 pts over 5 years
Net margin
12.8%+42.5 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +16.0% | +20.4% | +34.5% | +26.4% | |
| Gross profit | +21.6% | +27.3% | – | +29.2% | |
| Operating income | +257.9% | – | – | – | |
| Net income | +174.9% | – | – | – | |
| EPS, diluted | +164.5% | – | – | – | |
| Free cash flow | +98.5% | – | – | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | -10.6% | 5.3% | |
| Return on assets | – | -9.5% | 4.9% | |
| Current ratio | 6.38 | 22.39 | 8.15 | |
| Debt to equity | 0.42 | 0.00 | – | |
| Net debt to EBITDA | 1.38× | 12.72× | – | |
| Interest coverage | -10.4× | -154.5× | – | |
| Inventory turnover | 7.0× | – | 7.3× | |
| Capex to revenue | 6.5% | 2.4% | 1.9% | |
| Diluted shares | 29M | 53M | 81M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Veracyte generated $294.78M from operations and spent $44.85M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$294.78M
Used
$44.85M
Capital expenditure$44.85M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin12.8%
×Asset turnover0.38×
×Equity multiplier1.09×
=Return on equity, FY20255.3%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | 12.8% | 0.38× | 1.09× | 5.3% |
| FY2024 | 5.4% | 0.37× | 1.09× | 2.2% |
| FY2023 | -20.6% | 0.32× | 1.07× | -7.0% |
| FY2022 | -12.3% | 0.25× | 1.08× | -3.4% |
| FY2021 | -34.4% | 0.27× | 1.08× | -10.0% |
| FY2020 | -29.7% | 0.32× | 1.11× | -10.6% |
| FY2019 | -10.5% | 0.61× | 1.24× | -7.9% |
| FY2018 | -25.0% | 0.92× | 1.70× | -39.3% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
6of 8 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero$66.35M
- Cash generatingOperating cash flow above zero$136.31M
- Return on assets improvedROA up on the prior year2.2% → 5.1%
- Earnings backed by cashOperating cash flow above net income$136.31M vs $66.35M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose4.73 → 8.15
- No dilutionShare count did not rise78M → 81M
- Gross margin improvedGross margin up on the prior year66.88% → 70.10%
- More efficientAsset turnover rose0.40 → 0.40